ContraFect Corporation (NASDAQ:CFRX) reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $0.98 and last traded at $0.95, with a volume of 426,475 shares trading hands. The stock had previously closed at $1.00.

Separately, Maxim Group reiterated a “hold” rating on shares of ContraFect Corporation in a report on Thursday, May 25th.

The firm’s market capitalization is $73.66 million. The firm’s 50-day moving average is $1.21 and its 200 day moving average is $1.53.

ContraFect Corporation (NASDAQ:CFRX) last posted its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.11. Analysts anticipate that ContraFect Corporation will post ($0.43) earnings per share for the current fiscal year.

In other news, Director Sol J. Barer acquired 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The stock was purchased at an average price of $1.24 per share, with a total value of $49,600.00. Following the purchase, the director now owns 815,933 shares of the company’s stock, valued at approximately $1,011,756.92. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders purchased a total of 50,800 shares of company stock valued at $62,992 in the last ninety days. Company insiders own 9.30% of the company’s stock.

An institutional investor recently bought a new position in ContraFect Corporation stock. Westfield Capital Management Co. LP acquired a new position in ContraFect Corporation (NASDAQ:CFRX) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 149,600 shares of the biotechnology company’s stock, valued at approximately $269,000. Westfield Capital Management Co. LP owned 0.36% of ContraFect Corporation as of its most recent filing with the SEC. 24.45% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “ContraFect Corporation (CFRX) Hits New 52-Week Low at $0.98” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at

ContraFect Corporation Company Profile

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.